360 related articles for article (PubMed ID: 24138302)
1. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
5. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase inhibitors in melanoma.
Eigentler TK; Meier F; Garbe C
Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
8. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
9. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
10. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
An Q; Liu Z
BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
[TBL] [Abstract][Full Text] [Related]
14. BRAF inhibitors and melanoma.
Flaherty KT
Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
[TBL] [Abstract][Full Text] [Related]
15. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
Zhou AY; Johnson DB
Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
Malissen N; Grob JJ
Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
[TBL] [Abstract][Full Text] [Related]
19. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
